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Systemic sclerosis is a connective tissue disease characterized by ﬁbrosis of the skin, internal organs, and widespread vasculopathy.
Raynaud’s phenomenon and digital ulcers are vascular manifestations of this disease and cause signiﬁcant morbidity. Current
treatments are only moderately eﬀective in reducing the severity of Raynaud’s in a portion of patients and typically do not lead
to substantial beneﬁt in terms of the healing or prevention of digital ulcers. Several studies have evaluated the eﬃcacy of targeting
the vasoconstrictor endothelin-1 for the treatment of systemic sclerosis-associated vascular disease. The purpose of this paper is
to summarize the published studies and case reports evaluating the eﬃcacy of endothelin receptor antagonists in the treatment of
Raynaud’s phenomenon and digital ulcers associated with systemic sclerosis.
1.Introduction
Systemic sclerosis (SSc) is a connective tissue disease char-
acterized by ﬁbrosis of the skin and internal organs and
widespread vasculopathy. Raynaud’s phenomenon (RP) is
often the ﬁrst manifestation of SSc, frequently preceding the
onset of cutaneous sclerosis by several years particularly in
patientswithlimiteddisease,andeventuallyoccursin95%of
patients with SSc [1]. Vasospasm of the digital arteries leads
tothethreecharacteristicphasesofpallor,cyanosis,thenery-
thema correlating with reduced blood ﬂow, total loss of oxy-
gen supply, and reperfusion. Episodes of RP are usually trig-
gered by cold exposure or stress and can be associated with
numbness and pain, resulting in signiﬁcant disability [2].
Recurrent episodes of ischemia-reperfusion injury and the
subsequent generation of reactive oxygen species can result
in ischemic damage to distal tissue sites. Digital ulcers (DUs)
are necrotic lesions that occur either at distal aspects of digits
(ﬁngers or toes) or over bony prominences and occur in
up to 50% of patients with limited or diﬀuse cutaneous
SSc [3]. These lesions are exquisitely painful, heal slowly,
and interfere with activities of daily living often leading
to substantial functional disability. Other complications
associated with DU include scarring with loss of distal tissue,
infection that can lead to osteomyelitis, and progression to
gangrene requiring amputation [4, 5]. DUs that develop at
distal aspects of digits are thought to be related to recurrent
ischemia from various processes, including vasospasm from
RP, thrombosis of digital arteries, calcinosis, and structural
microvascular changes related to the underlying SSc [4, 6–8].
Recurrenttrauma,particularlyinpatientswithjointcontrac-
tures, also contributes to the development of DU in patients
with SSc. Ulcerations on the lower extremities proximal to
the feet can occur in patients with SSc who likely have
macrovascular disease as well. Current treatments for both
RPandDUconsistofvasodilatorsincludingcalciumchannel
blockers (CCBs), alpha-adrenergic inhibitors, angiotensin
converting enzyme (ACE) inhibitors, angiotensin receptor
blockers, and nitroglycerin analogues. These medications
are moderately eﬀective in reducing the severity of RP in a
portion of SSc patients [9], but typically do not lead to sub-
stantial beneﬁt in terms of the healing and prevention of DU.
With the availability of powerful vasodilator therapies
for the treatment of pulmonary arterial hypertension (PAH),
options for the treatment of severe RP, DU, and progressive
digital ischemia have increased. Prostacyclin analogues have
been shown to accelerate the healing of DU, however, those
agents found to be eﬀective thus far require intravenous or2 International Journal of Rheumatology
subcutaneous delivery [10–12]. Small studies have indicated
that oral phosphodiesterase-5 inhibitors (PDE-5-I) are eﬀec-
tive in reducing the severity of RP and promoting the healing
of DU [13–15]. Large multicenter randomized controlled
studies are underway to further evaluate the eﬃcacy of
PDE-5-I in the treatment of RP and DU. Several studies
have evaluated the eﬃcacy of targeting the vasoconstrictor
endothelin-1 (ET-1) for the treatment of RP and/or DU. The
purpose of this paper is to summarize the published studies
evaluating endothelin receptor antagonists (ETRA) in the
treatment of RP and/or ischemic DU associated with SSc.
2. The Role of Endothelininthe Pathogenesis
ofSSc-AssociatedRP andDU
The initial events leading to SSc vasculopathy are thought
to involve endothelial cell injury [16] with subsequent loss
of normal vasodilatory mediators such as prostacyclin and
nitricoxide[17–20].Inaddition,endothelialinjuryresultsin
increased release of the vasoconstrictor endothelin-1 (ET-1)
[21, 22]. ET-1 is a 21-amino acid polypeptide expressed
primarily by endothelial cells, but has also been found to
be expressed by epithelial cells, macrophages, ﬁbroblasts,
and cardiomyocytes among others [23, 24]. It acts locally,
binding to the surface of smooth muscle cells and acts on
the vascular endothelium itself in an autocrine manner.
Levels of ET-1 have been found to be increased in the serum
of patients with RP and SSc [25–27]. In addition to its
role as a biomarker of vascular disease, ET-1 itself may be
contributing to the ﬁbrotic and vasculopathic aspects of SSc
as it has been shown to stimulate ﬁbroblast and smooth
muscle proliferation [28, 29]. ET-1 signaling is mediated
by two transmembrane G-protein-coupled receptors (ETA
and ETB)w i t hd i ﬀerent binding aﬃnity and physiologic
eﬀects [23, 30]. ETA receptors are expressed on vascular
smooth muscle cells and primarily mediate vasoconstriction
whereas ETB receptors are expressed on both endothelial
cells, mediating vasodilatation, and on smooth muscle cells,
mediating vasoconstriction [31].
3. Endothelin Receptor Antagonists
Endothelin receptor antagonists are a class of PAH-speciﬁc
drugs that block the interaction of ET-1 with its receptors
(Table 1). ETRAs can selectively act on ETAreceptors to vary-
ing degrees, thus interfering with the vasoconstrictive eﬀects
of ET-1. Those with a relatively low ETA/ETB selectivity
are traditionally considered nonselective. Both nonselective
and selective ETRAs have shown eﬃcacy in the treatment
of PAH and currently two are approved for this indication
in the USA: bosentan and ambrisentan [32–35]. Sitaxsentan
was approved in Europe, Canada, and Australia in 2006,
but withdrawn from the market in 2010 due to concerns
about severe liver toxicity. Case reports of patients showing
improvement in their RP and DU while undergoing therapy
withETRAsforPAHhaveledtorandomizedcontrolledtrials
investigating the eﬃcacy of these agents for the treatment
of RP and DU in patients with SSc. As a result of two large
randomized controlled trials, bosentan was approved for the
prevention of DU in SSc patients in the European Union
in June 2007. We will now review the published literature
describing the use of ETRAs in the treatment of RP and/or
DU in patients with SSc.
3.1. Case Reports. Table 2 summarizes the case reports
describing the eﬃcacy of ETRAs in the treatment of SSc-
associated cutaneous ulcers. The ﬁrst case report published
in 2003 described a 50-year-old male with diﬀuse cuta-
neous SSc and severe PAH who was enrolled in a double-
blind, placebo-controlled study investigating the eﬃcacy and
safety of bosentan in patients with PAH (the BREATHE-1
study [32, 36]). During the open-label extension phase of
the study, he received bosentan 62.5mg twice daily and
within 4 weeks of this therapy, his leg and other small
nonacral skin ulcers on his trunk and extremities had
healed. In 2006, there were two published case reports
describing the eﬃcacy of bosentan in treating cutaneous
ulcerations in sclerodermatous conditions. The ﬁrst case
described a 61-year-old female with limited cutaneous SSc
and multiple DU refractory to CCB and IV prostacyclin
therapy [37]. After 6 months of standard bosentan therapy
(62.5mgBID× 4 weeks then 125mg BID), she experienced
resolution of her DU correlating with a decrease in plasma
ET-1 concentration. The second case reported a 4-year-
old girl with pansclerotic morphea unresponsive to cor-
ticosteroids, methotrexate, CCB, ACE-inhibitors, and D-
penicillamine [38]. Within the ﬁrst months of bosentan
therapy, both her widespread sclerotic skin lesions and her
limb ulcers improved. Another case report published in 2007
described a 39-year-old female with limited cutaneous SSc
and worsening DU despite IV prostacyclin therapy [39].
After 6 weeks of the standard approved dose of bosentan,
her DU completely healed. In 2008, a report was published
describing a 62-year-old female with long-standing SSc who
experienced healing of a large pretibial ulceration after 6
months of standard bosentan therapy [40]. Finally, in 2009,
a case report described a 39-year-old female with diﬀuse
cutaneous SSc and recalcitrant DU treated with sitaxsentan
100mg daily. After 6 months of therapy, her DU signiﬁcantly
improved and no new DU developed [41].
3.2. Open-Label Studies. Table 3 outlines the prospective
studies investigating the utility of ETRAs in the treatment of
RP and/or DU. The ﬁrst prospective study published in 2006
described 3 patients with RP in the setting of prescleroderma
(deﬁned as RP associated with sclerodermatous nailfold
capillaroscopic changes and SSc-speciﬁc autoantibodies) or
limited cutaneous SSc independent of a history of DU [43].
The participants received the standard dosing of bosentan
and at the end of the 16-week treatment course pain, RP
disease activity and severity were noted to be reduced. A
larger prospective observational study published in 2008
evaluated the long-term eﬃcacy and tolerability of bosentan
in 15 patients with SSc with current or a prior history of DU
[44]. The patient population in the study was particularly
heterogeneouswithawiderangeinage(11–72years),0to26
DU at baseline, and included 6 patients with interstitial lungInternational Journal of Rheumatology 3














FDA approved for use in the USA in November 2001 for WHO functional
class III/IV PAH then extended to include WHO class II in 2009. Approved in
the EU for WHO functional class III PAH in May 2002. In June 2007, the EU
approved and extended the indication of bosentan as a therapy to reduce the







FDA approved for the once-daily treatment of WHO functional class II/III
PAH in June 2007. It was later approved by the European Medicines Agency
for the same indication in the EU in April 2008.
Sitaxsentan 100mg daily 6500x
Approved in the EU in August 2006, then in Canada and Australia in March
2007 for the once-daily treatment of WHO functional class III PAH. On
December 10, 2010, the manufacturer voluntarily removed sitaxsentan from
the market and halted clinical trials due to concerns about liver toxicity.
FDA: Food and Drug Administration, EU: European Union, PAH: pulmonary arterial hypertension, DU: digital ulcer(s), RP: Raynaud’s phenomenon, and
SSc: systemic sclerosis.
Table 2: Case reports of the eﬃcacy of endothelin receptor antagonists for systemic sclerosis-associated cutaneous ulcers.
















Received bosentan 62.5mg twice daily and within 4
weeks of this therapy his leg and other small nonacral
skin ulcers on his trunk and extremities had healed.









Bosentan was initiated at the standard approved dose of
62.5mg twice daily for a month then 125mg twice
daily. After 6 months, she experienced resolution of her
DU correlating with a decrease in plasma ET-1










Bosentan was started at an initial dose of 31.25mg four
times daily for 4 weeks, and then decreased to the
standard dose for her weight of 31.25mg twice daily.
Within the ﬁrst months of bosentan therapy, both her





with limited SSc DU IV prostacyclin
Bosentan was initiated at the standard approved dose
and after 6 weeks of this therapy her DU completely











Bosentan was initiated at the standard approved dose
with improvement in the ulcer seen during the ﬁrst few
months of therapy. Complete healing of the large









Treated with sitaxsentan 100mg daily; during the 6
months of treatment there was a decrease in pain and
near complete healing of preexisting DU and no
development of new DU.
∗Treatments noted in the case report only; other treatments may have been used.
SSc: systemic sclerosis, DU: digital ulcers, PAH: pulmonary arterial hypertension, CCB: calcium channel blocker, ET-1: endothelin-1, ACE: angiotensin
converting enzyme, and PUVA: psoralen plus ultraviolet A.4 International Journal of Rheumatology
Table 3:Studiesevaluatingeﬃcacyofendothelinreceptorantagonistsforsystemicsclerosis-associatedraynaud’sphenomenonand/ordigital
ulcers.










Korn et al. 2004
RAPIDS-1 [42] R, PC, DB
(a) 62.5mg
bosentan BID × 4
weeks; 125mg
BID × 12 weeks
(b) Placebo BID ×
16 weeks
(a) 79/66






Patients receiving bosentan had
a 48% reduction in the mean
number of new DU at the end of
the treatment period (P = 0.0083).
No diﬀerence between groups in the
healing of existing ulcers.
Selenko-Gebaue
et al. 2006 [43] Obs
62.5mg bosentan
BID × 4w e e k s ;
125mg BID × 12
weeks
3/3 16 weeks RP activity and
pain severity.
Pain, RP disease activity, number







BID × 4w e e k s ;
then 125mg BID
15 4 to 36 months Number and
severity of DU.
There was a decrease in the number
of DU. A trend towards eﬃcacy was
seen in the number of healed ulcers




BID × 4w e e k s ;
then 125mg BID






After a median 8 weeks of
treatment, 13 out of 15 patients had
improved RP. DU also improved
after a median 12 weeks’ treatment




BID × 4w e e k s ;
then 125mg BID
26/23 36 months Number of new
and healed DU.
The mean number of DU per
p a t i e n tw a sr e d u c e da t6 ,1 2 ,a n d3 6
months (P<0.001).
Nguyen et al.
2010 [47] R, PC, DB
(a) 62.5mg
bosentan BID × 4
weeks; 125mg









Compared with placebo, bosentan
did not signiﬁcantly reduce the
severity, frequency, duration, or




BID × 4w e e k s ;
125mg BID
10/8 24 weeks Healing of
current DU.
Bosentan increased the number of
healed DU from 42% at baseline to










Number and duration of RP attacks
showed a statistically signiﬁcant
decrease at 12 weeks and







bosentan BID × 4
weeks; 125mg










Bosentan treatment was associated
w i t ha3 0 %r e d u c t i o ni nt h e
number of new DU compared with
placebo (P = 0.04). No diﬀerence
between groups in healing rate of
preexisting ulcers.
R: randomized, PC: placebo controlled, DB: double blind, Obs: observational, DU: digital ulcer, RP: Raynaud’s phenomenon, and RCS: Raynaud’s Condition
Score.
disease and 3 with PAH. They were treated with bosentan
therapy at standard doses and were followed for a mean of
24.7 months (range 4–36 months). There was a signiﬁcant
decrease in the mean number of DU per patient from 5 at
baseline to 0.4 at 12 months (P<0.05). In 2009, an obser-
vational study was published on 15 patients with connective
tissue disease associated PAH that speciﬁcally evaluated the
eﬀe c to fb o s e n t a no nD Ua n dR P[ 45]. After a median of 8
weeks of treatment, 13 out of 15 patients had improved RP
severity with 8 patients experiencing disappearance of all
RP symptoms after a mean of 14 weeks. Healing of DU was
observed after a median of 20 weeks (range 16–24 weeks)
for 6 of the 8 patients who had DU at baseline. The longest
prospective open label study of bosentan was a 3 year trial
of 26 patients with DU refractory to CCB, ACE-inhibitors or
sildenaﬁl, published in 2009 [46]. Complete healing of DU
occurred in 17 of the 26 participants (65%) after a median
period of 25 weeks (range 8–26 weeks), and improvementInternational Journal of Rheumatology 5
was noted in the DU of 4 additional patients. Overall, the
mean number of DU per patient was reduced at 6, 12,
and 36 months (P<0.001). Additionally, healing of the
DU was evidenced by complete reepithelialization on skin
biopsy which was performed on 5 of the 26 participants.
In a 24-week prospective open-label trial, 10 patients with
SSc were treated with bosentan; skin ﬁbrosis as assessed by
the modiﬁed Rodnan skin score (MRSS) was the primary
endpoint, but evaluation of DU was a secondary outcome
assessment [48]. At each visit, examination of DU was
performed by the same evaluator and categorized as present,
indeterminate (>50% reduction in their surface area), or
healed (total reepithelialization). 88% of DU were catego-
rizedashealedattheendofthe24-weektreatmentcompared
with 42% at baseline (P = 0.0019). Finally, in 2010, a 48-
week observational study was published evaluating the
eﬀectiveness of bosentan for RP without DU in patients with
SSc-associated PAH [49]. 14 patients who were on stable
doses of other PAH-speciﬁc therapies (excluding patients
treated with parenteral prostanoids within the previous 6
months) were treated with bosentan as add-on therapy. For
patients with limited or diﬀuse cutaneous SSc, the number
of RP attacks from baseline to 48 weeks decreased from
3.4 ± 1.8t o2 .1 ± 1.4a n d3 .8 ± 1.7t o2 .1 ± 1.8, respectively
(P<0.05).Likewise,thedurationofRPattacksdecreasedfor
patients with limited or diﬀuse cutaneous SSc from baseline
to 48 weeks from 62.5 ± 43.7t o2 2 .1 ± 13.8m i n u t e sa n d
61.0 ±38.9t o2 9 .2 ±13.7 minutes, respectively (P<0.01).
3.3. Double-Blind, Randomized, Placebo-Controlled Studies.
The ﬁrst randomized placebo-controlled double-blind clin-
ical trial evaluating an ETRA for the prevention of DU in
patients with SSc was published in 2004 and is commonly
known as the RAPIDS-1 (Randomized Placebo-controlled
Investigation of Digital ulcers in Scleroderma) trial [42]. 122
patients with SSc and current DU or a history of at least 1
in the prior 12 months, enrolled across 17 centers in Europe
and North America. 79 were randomized to receive bosentan
and 43 to receive matching placebo during the 16-week
treatment phase. The mean number of new ulcers during the
treatment period was 1.4 for patients on bosentan versus 2.7
for patients on placebo (P = 0.0083) representing a 48%
reduction in the number of new DU. However, there were
no diﬀerences in the reduction of preexisting DU in the 63%
of patients with active DUs at baseline. The most notable
adverse event occurring in more patients on bosentan than
placebo was elevated transaminase levels (14% versus 0%). 3
patientsdevelopedamarkedtransaminitis(>8xULN),and5
patients (6%) discontinued the study due to these laboratory
abnormalities, but in all cases the transaminase values
returned to normal when bosentan was discontinued. The
results of a second randomized placebo-controlled double-
blind clinical trial investigating bosentan for the treatment of
SSc-related DU (RAPIDS-2) were recently published in 2011
[50]. This trial involved a longer 24-week treatment phase
and all 188 patients enrolled across 41 sites in Europe and
North America were required to have at least 1 active DU,
the largest called the “cardinal ulcer,” at baseline. The mean
number of new DU over 24 weeks was 1.9 ± 0.2f o rp a t i e n t s
on bosentan versus 2.7 ± 0.3 for patients on placebo (P =
0.035) representing a 30% reduction in the number of new
lesions. As with the RAPIDS-1 study, the RAPIDS-2 study
failed to show a beneﬁt in terms of healing of existing ulcers.
Adverse events occurring in more patients on bosentan than
placebo included peripheral edema (18.8% versus 4.4%) and
elevated aminotransferases (12.5% versus 2.2%). Markedly
increased aminotransferases (>3x upper limit of normal
(ULN)and1caseof>8xULN)occurredin10.5%ofpatients
in the bosentan group, but these abnormalities resolved
during continued treatment, after a decrease in dose, or
following temporary or permanent treatment discontinua-
tion. Only one placebo-controlled double-blind clinical trial
evaluating an ETRA for the treatment of RP in patients with
SSc has been published to date [47]. 17 patients without
preexistingDUwererandomizedtoeitherstandardbosentan
therapy or matching placebo during the 16-week treatment
phase. Severity of RP was assessed via the Raynaud’s Con-
dition Score (RCS), a validated composite self-assessment of
the severity of RP encompassing the number and duration
of episodes, the associated symptoms, such as pain and
numbness, and the degree of hand disability. The RCS is
measured on a scale of 0–10 with 0 indicating no disability
related to RP and 10 indicating extremely severe disability
from RP. Patients recorded the frequency, duration, and
severity of RP attacks in daily symptom diaries. The mean
RCS score was reduced for both the bosentan and placebo
groups(−31%and −36%)atweek16,buttheimprovements
were not statistically signiﬁcant compared with baseline nor
were they diﬀerent between the groups. Frequency of RP
attacks signiﬁcantly decreased in the bosentan and placebo
groups, however, at week 16 only patients in the placebo
group maintained a statistically signiﬁcant decrease in RP
frequency (bosentan: −30%; placebo: −57%, P = 0.017).
In 16 weeks, a signiﬁcant reduction in mean duration of RP
attacks was observed for both bosentan (−26%; P = 0.012)
and placebo (−60%; P = 0.028) compared with baseline,
however, there was no signiﬁcant diﬀerence between the
groups. Interestingly, despite the lack of improvement on
measures of RP activity and severity with bosentan, patients
in the treatment group demonstrated statistically signiﬁcant
improvements in functional status as assessed by the scle-
roderma Health Assessment Questionnaire (P = 0.03 and
P = 0.01 at weeks 12 and 20, respectively) and the UK
functional score (P = 0.04 at weeks 8 and 16) compared with
those treated with placebo. No serious adverse events were
noted, and only 1 participant withdrew due to treatment-
related peripheral edema. The authors did mention that DU
developed in 1 patient on placebo and 2 on bosentan, but
these resolved with similar healing times.
4. Conclusion
The ﬁndings from the literature reviewed here indicate
that ETRAs may play a role in the treatment of RP and
DU in addition to their indication for the treatment of
PAH. The two large, randomized, placebo-controlled studies
using bosentan have shown that this agent is useful in the
preventionofnewDUinpatientswithSSc(RAPIDS1and2)6 International Journal of Rheumatology
conﬁrming ﬁndings in uncontrolled observational studies.
However, both of these studies failed to show a beneﬁt in
terms of healing of existing ulcers [42, 50]. Although obser-
vational studies demonstrated an improvement in RP with
ETRA treatment [43, 45, 49], the one randomized, placebo-
controlled study using bosentan for the treatment of RP [47]
did not show a statistically signiﬁcant diﬀerence between
bosentan and placebo. Although this was a relatively small
study, the results highlight the importance of performing
RCT in the assessment of potential treatments for RP and
DU. In addition to the beneﬁt of ETRA for DU, 3 of the
case reports suggested beneﬁt in nondigital ischemic ulcers
in patients with SSc, but larger studies are necessary to verify
these results [36, 38, 40]. This is important as nondigital
ulcers are seen in up to 4% of patients with SSc [51].
The majority of studies published thus far have described
the eﬀects of the ETRA bosentan on RP and/or DU. It is
unknownwhetherETRAswithgreaterselectivityfortheETA
receptor, would show better tolerability and eﬃcacy than
bosentan in the treatment of SSc-associated RP and DU.
Ambrisentan may be preferable to bosentan given the lower
incidence of liver function test abnormalities, once daily
dosing and lack of interaction with warfarin. Our center has
recently completed the ﬁrst open-label prospective study of
ambrisentan for the treatment of SSc-associated DU and the
results will soon be available. ETRAs may be preferable to
prostacyclins given their oral bioavailability, but physicians
must be cognizant of their teratogenicity and potential
side eﬀects including liver toxicity, edema, and anemia.
Additional RCTs are necessary to better assess the role of
ETRAs for the treatment of RP and DU in patients with SSc.
References
[1] J. H. Korn, “Pathogenesis of systemic sclerosis,” in Arthritis
and Allied Conditions, W. J. Koopman, Ed., pp. 1643–1654,
Williams & Wilkins, Baltimore, Md, USA, 2001.
[2] F. M. Wigley, “Vascular disease in scleroderma,” Clinical
Reviews in Allergy and Immunology, vol. 36, no. 2-3, pp. 150–
175, 2009.
[3] C. Ferri, G. Valentini, F. Cozzi et al., “Systemic sclerosis:
demographic, clinical, and serologic features and survival in
1,012 Italian patients,” Medicine, vol. 81, no. 2, pp. 139–153,
2002.
[4] L. K. Hummers and F. M. Wigley, “Management of Raynaud’s
phenomenon and digital ischemic lesions in scleroderma,”
Rheumatic Disease Clinics of North America,v o l .2 9 ,n o .2 ,p p .
293–313, 2003.
[5] L. Chung and D. Fiorentino, “Digital ulcers in patients with
systemic sclerosis,” Autoimmunity Reviews, vol. 5, no. 2, pp.
125–128, 2006.
[6] V. Steen, C. P. Denton, J. E. Pope, and M. Matucci-Cerinic,
“Digital ulcers: overt vascular disease in systemic sclerosis,”
Rheumatology, vol. 48, supplement 3, pp. 19–24, 2009.
[7] C. Denton and J. Korn, “Digital ulceration and critical digital
ischemia in scleroderma,” Journal of the Scleroderma Clinical
Trials Consortium, vol. 1, no. 2, pp. 12–16, 2003.
[8] F. Galluccio and M. Matucci-Cerinic, “Two faces of the same
coin: raynaud phenomenon and digital ulcers in systemic
sclerosis,” Autoimmunity Reviews, vol. 10, no. 5, pp. 241–243,
2010.
[9] A. E. Thompson, B. Shea, V. Welch, D. Fenlon, and J. E. Pope,
“Calcium-channel blockers for Raynaud’s phenomenon in
systemic sclerosis,” Arthritis and Rheumatism,v o l .4 4 ,n o .8 ,
pp. 1841–1847, 2001.
[10] D.B.Badesch,V.F.Tapson,M.D.McGoonetal.,“Continuous
intravenous epoprostenol for pulmonary hypertension due
to the scleroderma spectrum of disease: a randomized,
controlled trial,” Annals of Internal Medicine, vol. 132, no. 6,
pp. 425–434, 2000.
[11] L. Chung and D. Fiorentino, “A pilot trial of treprostinil for
the treatment and prevention of digital ulcers in patients
with systemic sclerosis,” Journal of the American Academy of
Dermatology, vol. 54, no. 5, pp. 880–882, 2006.
[ 1 2 ]F .M .W i g l e y ,J .R .S e i b o l d ,R .A .W i s e ,D .A .M c C l o s k e y ,a n d
W. P. Dole, “Intravenous iloprost treatment of Raynaud’s phe-
nomenonandischemiculcerssecondarytosystemicslcerosis,”
Journal of Rheumatology, vol. 19, no. 9, pp. 1407–1414, 1992.
[13] J. Gore and R. Silver, “Oral sildenaﬁl for the treatment of
Raynaud’s phenomenon and digital ulcers secondary to
systemic sclerosis,” Annals of the Rheumatic Diseases, vol. 64,
no. 9, article 1387, 2005.
[14] C. S. Brueckner, M. O. Becker, T. Kroencke et al., “Eﬀect of
sildenaﬁl on digital ulcers in systemic sclerosis: analysis from
a single centre pilot study,” Annals of the Rheumatic Diseases,
vol. 69, no. 8, pp. 1475–1478, 2010.
[ 1 5 ]P .D .S h e n o y ,S .K u m a r ,L .K .J h ae ta l . ,“ E ﬃcacy of tadalaﬁl
in secondary Raynaud’s phenomenon resistant to vasodilator
therapy: a double-blind randomized cross-over trial,”
Rheumatology, vol. 49, no. 12, Article ID keq291, pp.
2420–2428, 2010.
[ 1 6 ]P .M .C a m p b e l la n dE .C .L e R o y ,“ P a t h o g e n e s i so fs y s t e m i c
sclerosis: a vascular hypothesis,” Seminars in Arthritis and
Rheumatism, vol. 4, no. 4, pp. 351–368, 1975.
[17] R. J. Gryglewski, R. M. Botting, and J. R. Vane, “Mediators
produced by the endothelial cell,” Hypertension,v o l .1 2 ,n o .6 ,
pp. 530–548, 1988.
[18] S.Kourembanas,L.P.McQuillan,G.K.Leung,andD.V.Faller,
“Nitric oxide regulates the expression of vasoconstrictors and
growth factors by vascular endothelium under both normoxia
and hypoxia,” The Journal of Clinical Investigation, vol. 92, no.
1, pp. 99–104, 1993.
[19] T. Yamamoto, I. Katayama, and K. Nishioka, “Nitric oxide
production and inducible nitric oxide synthase expression in
systemic sclerosis,” Journal of Rheumatology, vol. 25, no. 2, pp.
314–317, 1998.
[20] T. R. Katsumoto, M. L. Whitﬁeld, and M. K. Connolly,
“The pathogenesis of systemic sclerosis,” Annual Review of
Pathology, vol. 6, pp. 509–537, 2011.
[21] M. Yanagisawa, A. Inoue, Y. Takuwa, Y. Mitsui, M. Kobayashi,
and T. Masaki, “The human preproendothelin-1 gene:
possible regulation by endothelial phosphoinositide turnover
signaling,” Journal of Cardiovascular Pharmacology, vol. 13,
supplement 5, pp. S13–S17, 1989.
[22] A. Inoue, M. Yanagisawa, S. Kimura et al., “The human
endothelin family: three structurally and pharmacologically
distinct isopeptides predicted by three separate genes,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 86, no. 8, pp. 2863–2867, 1989.
[23] G. M. Rubanyi and M. A. Polokoﬀ, “Endothelins: molecular
biology, biochemistry, pharmacology, physiology, and
pathophysiology,” Pharmacological Reviews,v o l .4 6 ,n o .3 ,p p .
325–415, 1994.International Journal of Rheumatology 7
[24] M.D.Mayes,“Endothelinandendothelinreceptorantagonists
in systemic rheumatic disease,” Arthritis and Rheumatism, vol.
48, no. 5, pp. 1190–1199, 2003.
[25] M. L. Biondi, B. Marasini, C. Bassani, and A. Agostoni, “In-
creased plasma endothelin levels in patients with Ray-naud’s
phenomenon,” The New England Journal of Medicine, vol. 324,
no. 16, pp. 1139–1140, 1991.
[26] K. Yamane, T. Miyauchi, N. Suzuki et al., “Signiﬁcance of
plasma endothelin-1 levels in patients with systemic sclerosis,”
Journal of Rheumatology, vol. 19, no. 10, pp. 1566–1571, 1992.
[ 2 7 ]M .R .Z a m o r a ,R .F .O ’ B r i e n ,R .B .R u t h e r f o r d ,a n dJ .V .W e i l ,
“Serum endothelin-1 concentrations and cold provocation in
primary Raynaud’s phenomenon,” The Lancet, vol. 336, no.
8724, pp. 1144–1147, 1990.
[28] M. B. Kahaleh, “Endothelin, an endothelial-dependent
vasoconstrictor in scleroderma: enhanced production and
proﬁbrotic action,” Arthritis and Rheumatism,v o l .3 4 ,n o .8 ,
pp. 978–983, 1991.
[29] V. Richard, V. Solans, J. Favre et al., “Role of endogenous
endothelin in endothelial dysfunction in murine model
of systemic sclerosis: tight skin mice 1,” Fundamental and
Clinical Pharmacology, vol. 22, no. 6, pp. 649–655, 2008.
[30] K. W. Frommer and U. M¨ uller-Ladner, “Expression and
function of ETA and ETB receptors in SSc,” Rheumatology,
vol. 47, supplement 5, pp. 27–28, 2008.
[31] M. Jain and J. Varga, “Bosentan for the treatment of
systemicsclerosis-associatedpulmonaryarterialhypertension,
pulmonary ﬁbrosis and digital ulcers,” Expert Opinion on
Pharmacotherapy, vol. 7, no. 11, pp. 1487–1501, 2006.
[32] R. N. Channick, G. Simonneau, O. Sitbon et al., “Eﬀects of the
dual endothelin-receptor antagonist bosentan in patients with
pulmonary hypertension: a randomised placebo-controlled
study,” The Lancet, vol. 358, no. 9288, pp. 1119–1123, 2001.
[33] L. J. Rubin, D. B. Badesch, R. J. Barst et al., “Bosentan therapy
for pulmonary arterial hypertension,” The New England
Journal of Medicine, vol. 346, no. 12, pp. 896–903, 2002.
[34] R. J. Oudiz, N. Gali` e, H. Olschewski et al., “Long-term
ambrisentan therapy for the treatment of pulmonary arterial
hypertension,” Journal of the American College of Cardiology,
vol. 54, no. 21, pp. 1971–1981, 2009.
[35] X. Shiwen, A. Leask, D. J. Abraham, and C. Fonseca,
“Endothelin receptor selectivity: evidence from in vitro and
pre-clinical models of scleroderma,” European Journal of
Clinical Investigation, vol. 39, supplement 2, pp. 19–26, 2009.
[36] M. Humbert and J. Cabane, “Successful treatment of systemic
sclerosis digital ulcers and pulmonary arterial hypertension
with endothelin receptor antagonist bosentan,” Rheumatology,
vol. 42, no. 1, pp. 191–193, 2003.
[ 3 7 ]J .T i l l o n ,F .H e r v ´ e ,D .C h e v a l l i e r ,J .F .M u i r ,H .L e v e s q u e ,
and I. Marie, “Successful treatment of systemic sclerosis-
related digital ulcers and sarcoidosis with endothelin receptor
antagonist(bosentan)therapy,”BritishJournalofDermatology,
vol. 154, no. 5, pp. 1000–1002, 2006.
[ 3 8 ]R .R o l d a n ,G .M o r o t e ,M .D .C .C a s t r o ,M .D .M i r a n d a ,J .C .
Moreno, and E. Collantes, “Eﬃcacy of bosentan in treatment
ofunresponsivecutaneousulcerationindisablingpansclerotic
morphea in children,” Journal of Rheumatology, vol. 33, no.
12, pp. 2538–2540, 2006.
[39] M. Chamaillard, I. Heliot-Hosten, J. Constans, and A. Ta¨ ıeb,
“Bosentan as a rescue therapy in scleroderma refractory
digital ulcers,” Archives of Dermatology, vol. 143, no. 1, pp.
125–126, 2007.
[40] M. E. G. Ferreira and M. A. Scheinberg, “Successful
treatment with bosentan of non-digital skin ulcers in
severe scleroderma,” Annals of the Rheumatic Diseases, vol. 67,
no. 12, pp. 1784–1785, 2008.
[41] P. Gholam, T. Sehr, A. Enk, and M. Hartmann, “Successful
treatment of systemic-sclerosis-related digital ulcers with a
selective endothelin type A receptor antagonist (sitaxentan),”
Dermatology, vol. 219, no. 2, pp. 171–173, 2009.
[42] J. H. Korn, M. Mayes, M. Matucci Cerinic et al., “Digital
ulcers in systemic sclerosis: prevention by treatment with
bosentan, an oral endothelin receptor antagonist,” Arthritis
and Rheumatism, vol. 50, no. 12, pp. 3985–3993, 2004.
[43] N. Selenko-Gebauer, N. Duschek, G. Minimair, G. Stingl,
and F. Karlhofer, “Successful treatment of patients with
severe secondary Raynaud’s phenomenon with the endothelin
receptor antagonist bosentan,” Rheumatology, vol. 45,
supplement 3, pp. 45–48, 2006.
[44] P. Garc´ ıa de la Pe˜ na-Lefebre, S. Rodr´ ıguez Rubio, M.
Valero Exp ´ osito et al., “Long-term experience of bosentan
for treating ulcers and healed ulcers in systemic sclerosis
patients,” Rheumatology, vol. 47, no. 4, pp. 464–466, 2008.
[45] M. Funauchi, K. Kishimoto, H. Shimazu et al., “Eﬀects of
bosentan on the skin lesions: an observational study from a
single center in Japan,” Rheumatology International, vol. 29,
no. 7, pp. 769–775, 2009.
[46] N. Tsifetaki, V. Botzoris, Y. Alamanos, E. Argyriou, A. Zioga,
and A. A. Drosos, “Bosentan for digital ulcers in patients
with systemic sclerosis: a prospective 3-year followup study,”
Journal of Rheumatology, vol. 36, no. 7, pp. 1550–1551, 2009.
[47] V. A. Nguyen, K. Eisendle, I. Gruber, B. Hugl, D. Reider, and
N. Reider, “Eﬀect of the dual endothelin receptor antagonist
bosentan on Raynaud’s phenomenon secondary to systemic
sclerosis: a double-blind prospective, randomized, placebo-
controlled pilot study,” Rheumatology,v o l .4 9 ,n o .3 ,p p .
583–587, 2009.
[48] A. Kuhn, M. Haust, V. Ruland et al., “Eﬀe c to fb o s e n t a no n
skin ﬁbrosis in patients with systemic sclerosis: a prospective,
open-label, non-comparative trial,” Rheumatology, vol. 49, no.
7, Article ID keq077, pp. 1336–1345, 2010.
[49] N. Giordano, L. Puccetti, P. Papakostas et al., “Bosentan
treatment for Raynauds phenomenon and skin ﬁbrosis in
patients with Systemic Sclerosis and pulmonary arterial
hypertension: an open-label, observational, retrospective
study,” International Journal of Immunopathology and Phar-
macology, vol. 23, no. 4, pp. 1185–1194, 2010.
[50] M. Matucci-Cerinic, C. P. Denton, D. E. Furst et al., “Bosentan
treatment of digital ulcers related to systemic sclerosis: results
from the RAPIDS-2 randomised, double-blind, placebo-
controlled trial,” Annals of the Rheumatic Diseases, vol. 70, no.
1, pp. 32–38, 2011.
[51] V. K. Shanmugam, P. Price, C. E. Attinger, and V. D. Steen,
“Lower extremity ulcers in systemic sclerosis: features and
response to therapy,” International Journal of Rheumatology,
vol. 2010, Article ID 747946, 8 pages, 2010.